查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1916852

腺病毒纯化试剂盒市场按技术、规格、等级、应用和最终用户划分－全球预测（2026-2032 年）

Adenovirus Purification Kit Market by Technology, Scale, Grade, Application, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 187 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2025 年，腺病毒纯化试剂盒市场价值将达到 12.3 亿美元，到 2026 年将成长至 13.4 亿美元，到 2032 年将达到 23.4 亿美元，复合年增长率为 9.63%。

主要市场统计数据
基准年 2025 12.3亿美元
预计年份：2026年 13.4亿美元
预测年份：2032年 23.4亿美元
复合年增长率 (%) 9.63%

对影响腺病毒纯化在研发和生产环境中优先事项的技术、法规和营运背景进行简明扼要的概述

腺病毒纯化是现代基因传递、疫苗研发和病毒学研究的关键步骤，需要严格控制其纯度、效力和可扩展性。近年来，载体工程技术的进步、病毒载体在治疗研发管线中应用的日益广泛以及监管要求的不断提高，使得纯化成为一个日益重要的交叉环节，直接影响下游製程的效率和生产经济性。本报告整合了技术发展、营运挑战和相关人员的需求，清楚阐述了影响纯化策略的策略要务。

技术融合、监管收紧和平台策略将如何重塑腺病毒纯化实践和商业性合作

由于技术进步的融合、监管要求的不断变化以及研发人员策略重点的转变，腺病毒纯化领域正经历着变革性的变化。例如，持续的製程强化推动了对单元操作的重新评估，并促使人们整合模组化解决方案，以在保持载体完整性的同时缩短保存时间。同时，自动化和封闭系统的兴起正在重塑实验室和生产设施在产能和污染控制之间取得平衡的方式，使得规模小规模的设施也能生产出稳定、高品质的产品。

评估2025年美国关税对采购、采购策略和生产连续性的营运和策略影响

美国将于2025年对部分进口商品加征关税，这项政策对生物製程材料的采购、生产计画以及整个全球供应链结构产生了连锁反应。层析法树脂、膜组件及相关耗材的采购决策已进行调整，以因应到岸成本和供应商经济状况的变化。为此，许多企业正在加快对替代供应商的区域资格认证，同时建立关键物料的库存缓衝，以防止生产中断。

将技术选择、应用需求、最终用户能力、规模考量和等级要求连结起来的实用細項分析，有助于优化策略和供应商选择。

深入理解分离过程对于开发满足不同使用者需求的纯化方法和商业策略至关重要。从技术角度来看，层析法是核心，其中亲和性和层析法、离子交换层析法和尺寸排除层析法各自发挥独特的作用。同时，渗滤、微滤和超过滤等过滤技术可以补充浓缩和缓衝液交换。硫酸铵沉淀和聚乙二醇（PEG）沉淀等沉淀技术则在特定领域有广泛的应用，尤其是在早期研发阶段，这些阶段对简便性和成本效益要求较高。这些技术差异会影响解析度、可扩展性和与下游分析的兼容性等决策标准。

区域架构：识别美洲、欧洲、中东和非洲以及亚太地区的发展对采购选择、监管协调和产能规划的影响

区域趋势对腺病毒纯化生态系的采购、监管合规和产能发展都有深远影响。在美洲，强大的生物製药製造群支撑着广泛的合约开发和生产活动，本地化的供应商网路和服务供应商能够实现快速的製程转移和规模化生产。这种集中化有利于合作开发模式的形成，但也导致对某些耗材和高性能材料的需求集中，这可能会在专案活动活性化期给供应链带来压力。

技术差异化、整合服务模式和策略伙伴关係关係如何影响腺病毒纯化供应商之间的竞争和韧性

腺病毒纯化领域的企业竞争格局取决于对差异化技术、垂直整合策略和服务型经营模式的投资。专注于高性能配体和膜创新的企业在产品品质和工艺经济性方面脱颖而出，而强调自动化和封闭式系统平台的企业则在易用性和适用性可扩展性方面展开竞争。包括合约组织和专业製程开发团队在内的服务供应商，透过提供整合开发、规模化和转移能力，将自身定位为客户团队的延伸。

为决策者提供关于平衡炼油创新、供应链韧性和监管准备的实用策略和营运建议

为了保持竞争力并满足不断变化的客户需求，产业领导者应同时专注于技术创新和营运韧性。优先投资于平台相容的纯化技术，以减少单元操作的变异性并加速载体平台之间的製程转移，同时扩展高解析度分析能力，从而实现快速的线上决策。加强与供应商的关係并对关键耗材进行多供应商认证，可减少对单一供应商的依赖，并在供应衝击期间提高业务连续性。

采用稳健的混合方法调查方法，结合专家访谈、技术检验和二手文献综述，确保了基于证据的分析和透明的限制。

我们的研究方法结合了定性和定量研究，旨在建立一个全面、以证据为基础的纯化方法和市场动态观点。主要研究包括对製程开发科学家、品质和法规专业人员、采购人员以及研发和生产机构的高阶主管进行结构化访谈，以获取有关技术应用、营运瓶颈和伙伴关係重点的第一手资讯。在条件允许的情况下，我们也透过现场考察和技术演示来补充这些访谈，以检验有关处理量、可重复性和易于实施性的说法。

策略整合重点阐述了实施综合炼油策略、供应商韧性和分析方法如何有助于降低专案风险并加快开发进度。

这项分析表明，腺病毒纯化正处于一个转折点，技术选择、区域趋势和策略采购决策正在汇聚，共同决定专案的敏捷性和下游流程的成功。纯化策略不再是后勤部门技术问题，而是影响临床试验时间、监管准备和生产成本结构的策略差异化因素。那些能够将纯化技术与特定应用需求相匹配、建立稳健的供应商网路并将高解析度分析融入流程控制的组织，将更有能力推进复杂的治疗和疫苗项目。

目录

第一章：序言

第二章调查方法

  • 研究设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查前提
  • 调查限制

第三章执行摘要

  • 首席体验长观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 产业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 上市策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会地图
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

8. 腺病毒纯化试剂盒市场（依技术划分）

  • 层析法
    • 亲和性和层析法
    • 离子交换层析法
    • 尺寸排阻层析法
  • 滤
    • 透析滤
    • 微滤
    • 超过滤
  • 降水法
    • 硫酸铵
    • PEG沉淀法

9. 腺病毒纯化试剂盒市场（依规格划分）

  • 商业的
  • 研究所

第十章 腺病毒纯化试剂盒市场（依等级划分）

  • 临床应用
  • 用于研究

第十一章 腺病毒纯化试剂盒市场（依应用划分）

  • 基因治疗
  • 研究
  • 疫苗生产

第十二章 腺病毒纯化试剂盒市场（依最终用户划分）

  • 学术机构
  • 生物製药公司
  • 契约製造组织
  • 受託研究机构

13. 各地区腺病毒纯化试剂盒市场

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十四章 腺病毒纯化试剂盒市场（依组别划分）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

15. 各国腺病毒纯化试剂盒市场

  • 美国
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十六章美国腺病毒纯化试剂盒市场

第十七章：中国腺病毒纯化试剂盒市场

第十八章 竞争格局

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • Abcam PLC
  • Bio-Rad Laboratories, Inc.
  • Danaher Corporation
  • Lonza Group AG
  • Merck KGaA
  • Promega Corporation
  • Repligen Corporation
  • Sartorius AG
  • Takara Bio Inc.
  • Thermo Fisher Scientific Inc.
  • WuXi Biologics
Product Code: MRR-AE420CB153AF

The Adenovirus Purification Kit Market was valued at USD 1.23 billion in 2025 and is projected to grow to USD 1.34 billion in 2026, with a CAGR of 9.63%, reaching USD 2.34 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 1.23 billion
Estimated Year [2026] USD 1.34 billion
Forecast Year [2032] USD 2.34 billion
CAGR (%) 9.63%

A concise foundational overview of the technical, regulatory, and operational context driving adenovirus purification priorities across research and manufacturing environments

Adenovirus purification is a cornerstone process in modern gene delivery, vaccine development, and virology research, demanding rigorous control of purity, potency, and scalability. Recent advances in vector engineering, increased adoption of viral vectors in therapeutic pipelines, and heightened regulatory expectations have elevated purification as a cross-functional discipline that directly affects downstream efficacy and manufacturing economics. This report synthesizes technological developments, operational challenges, and stakeholder needs to provide a clear view of the strategic imperatives shaping purification strategies.

The introduction frames the technical and commercial context that influences procurement, process development, and capacity planning. It considers how laboratory practices, clinical-grade manufacturing requirements, and investigator-driven research use converge to create diverse performance criteria. By examining the interplay between chromatography, filtration, and precipitation approaches alongside application-specific demands such as gene therapy and vaccine production, the introduction sets the stage for deeper analysis of supply-chain resilience, regulatory alignment, and technology adoption trends.

How technological convergence, regulatory rigor, and platform strategies are reshaping adenovirus purification practice and commercial collaborations

The adenovirus purification landscape is undergoing transformative shifts driven by converging technological advancements, evolving regulatory expectations, and strategic shifts in developer priorities. Continuous process intensification, for example, is pushing teams to re-evaluate unit operations and integrate modular solutions that reduce hold times while preserving vector integrity. At the same time, the rise of automated and closed systems is reshaping how laboratories and manufacturing facilities balance throughput with contamination control, enabling smaller footprints to deliver consistently high-quality material.

Concurrently, materials science innovations are refining ligand chemistries and membrane performance, which together enhance selectivity and reduce non-specific adsorption. This is occurring as developers prioritize platform approaches that minimize re-development between vector variants. Regulatory agencies are also emphasizing robust impurity characterization and viral safety testing, prompting organizations to adopt orthogonal purification steps and invest in analytics that provide higher-resolution process understanding. As a result, partnerships between process developers, equipment suppliers, and service providers are becoming more strategic; firms align around shared roadmaps that accelerate time-to-clinic while managing technical risk.

Assessing the operational and strategic consequences of United States tariff measures introduced in 2025 on procurement, sourcing strategies, and manufacturing continuity

The introduction of tariffs on certain imported goods by the United States in 2025 has created a ripple effect across procurement, manufacturing planning, and global supply-chain architectures for bioprocessing inputs. Sourcing decisions for chromatography resins, membrane modules, and ancillary disposables have been reframed to account for changed landed costs and altered supplier economics. In response, many organizations have accelerated regional qualification of alternative vendors while increasing inventory buffers for critical items to prevent production interruptions.

These adjustments have also influenced capital expenditure timing for facilities that depend on imported specialized equipment. Procurement teams are increasingly evaluating total cost of ownership rather than upfront price alone, weighing factors such as installation lead times, local service capability, and spare-parts logistics. Trade policy shifts have further prompted manufacturers and contract partners to reassess multi-sourcing strategies, building redundancies into supplier networks and in some cases localizing critical inputs closer to production hubs. Ultimately, the tariff landscape has emphasized the need for cross-functional scenario planning that links procurement, supply-chain, and process development to maintain continuity and control operating margins.

Actionable segmentation analysis linking technology choices, application needs, end-user capabilities, scale considerations, and grade requirements to purification strategy and supplier selection

A nuanced understanding of segmentation is essential for tailoring purification approaches and commercial strategies across diverse user needs. From a technology perspective, chromatography remains central with distinct roles for affinity chromatography, ion exchange chromatography, and size exclusion chromatography, while filtration modalities such as diafiltration, microfiltration, and ultrafiltration serve complementary concentration and buffer-exchange functions. Precipitation techniques, including ammonium sulfate and PEG precipitation, continue to have niche applicability where simplicity and cost-efficiency are prioritized, particularly in early-stage or research-scale workflows. These technological distinctions impact decision criteria such as resolution, scalability, and compatibility with downstream analytics.

Application-driven segmentation highlights how gene therapy, research, and vaccine production impose different purity and regulatory thresholds, which in turn influence process architecture and supplier selection. End users vary in capabilities and priorities; academic institutes often prioritize flexibility and cost, biopharmaceutical companies emphasize regulatory alignment and scale, and contract manufacturing organizations together with contract research organizations balance throughput, reproducibility, and client-specific requirements. Scale considerations separate commercial from laboratory settings, informing choices around single-use versus stainless-steel equipment, process automation, and facility design. Finally, grade segmentation into clinical use and research use governs documentation, material traceability, and validation intensity, with clinical-grade workflows demanding more stringent controls and documentation practices. Interactions across these segmentation axes guide where investment in analytics, validation, and automation will deliver the greatest operational and strategic returns.

A regional framework that delineates how Americas, Europe Middle East & Africa, and Asia-Pacific dynamics influence procurement choices, regulatory alignment, and capacity planning

Regional dynamics exert a profound influence on procurement, regulatory compliance, and capacity development across the adenovirus purification ecosystem. In the Americas, strong biopharmaceutical manufacturing clusters support extensive contract development and manufacturing activity, with localized supplier networks and service providers that enable rapid process transfer and scaling. This concentration facilitates collaborative development models, though it also concentrates demand for specific consumables and high-performance materials, which can stress supply chains during periods of elevated program activity.

Europe, Middle East & Africa presents a diverse regulatory and operational tapestry where national agencies and pan-regional frameworks intersect; firms prioritize harmonized documentation and cross-border quality systems to support multicountry trials and production. Localized manufacturing investments frequently emphasize compliance with stringent pharmacopoeial standards and the ability to support clinical-grade output. Asia-Pacific continues to expand capacity across both established and emerging hubs, combining cost-effective manufacturing with rapid infrastructure deployment. This region also supports a growing base of specialized suppliers and service providers, making it a focal point for both commercial-scale production and contract services. Across all regions, organizations are balancing considerations of regulatory alignment, supplier proximity, and resilience to geopolitical or trade disruptions when designing their purification and procurement strategies.

How technology differentiation, integrated service models, and strategic partnerships define competitive positioning and resilience among adenovirus purification suppliers

Competitive dynamics among companies operating in the adenovirus purification space are shaped by investments in differentiated technologies, vertical integration strategies, and service-based business models. Companies that focus on high-performance ligands and membrane innovations differentiate through product quality and process economics, while those emphasizing automation and closed-system platforms compete on ease of use and fit-for-purpose scalability. Service providers, including contract organizations and specialized process development groups, position themselves as extensions of client teams by offering integrated packages that combine development, scale-up, and transfer capabilities.

Strategic partnerships and licensing arrangements are increasingly common as technology developers seek routes to market while minimizing capital intensity. Similarly, companies that offer modular, application-specific solutions-such as pre-packed columns or single-use filtration assemblies tuned for viral vectors-gain traction by reducing validation burdens for end users. Intellectual property around novel ligands, membrane coatings, and process analytics is a differentiator, as is the ability to supply consistent, well-documented clinical-grade materials. Ultimately, the most resilient firms blend robust technical offerings with responsive supply-chain models and services that de-risk client programs from early development through commercialization.

Practical strategic and operational recommendations that balance innovation in purification technology with supply-chain resilience and regulatory preparedness for decision-makers

Industry leaders should adopt a dual focus on technological innovation and operational resilience to remain competitive and responsive to evolving client needs. Prioritize investments in platform-compatible purification technologies that reduce unit-operation variability and accelerate process transfer across vector platforms, while simultaneously expanding capabilities in high-resolution analytics that enable rapid in-process decision-making. Strengthening supplier relationships and qualifying multiple vendors for critical consumables will reduce single-source exposure and enhance continuity during supply shocks.

Operationally, leaders should implement scenario-based procurement plans that align inventory strategies with program risk profiles and production calendars. Embrace modular facility design and single-use technologies where appropriate to shorten campaign lead times and reduce capital risk. From a commercial perspective, offer differentiated service tiers, including bespoke development packages and technical training that lower barriers to adoption for smaller developers. Finally, invest in regulatory intelligence and cross-functional teams that can translate evolving guidance into validated processes, ensuring that clinical-grade material meets both scientific and compliance expectations.

A robust mixed-methods research methodology integrating expert interviews, technical validation, and secondary literature review to ensure evidence-based analysis and transparent limitations

The research approach combines qualitative and quantitative inquiry to construct a comprehensive, evidence-based perspective on purification practices and market dynamics. Primary research included structured interviews with process development scientists, quality and regulatory professionals, procurement leads, and executives from development and manufacturing organizations to capture firsthand insights on technology adoption, operational bottlenecks, and partnership preferences. These conversations were augmented with site visits and technical demonstrations where possible to validate claims around throughput, reproducibility, and ease of implementation.

Secondary research involved systematic review of peer-reviewed literature, regulatory guidance documents, technical white papers, and public disclosures to contextualize technological trends and regulatory expectations. Cross-validation steps included triangulating interview findings with product specifications, performance claims, and published comparative studies. Data integrity was further reinforced through expert panel reviews and sensitivity checks to identify potential bias or gaps. Limitations of the methodology are acknowledged, including variability in publicly available technical metrics and differences in reporting standards across organizations; however, the combined methodological rigor ensures that conclusions are grounded in multiple, independent information streams.

Strategic synthesis emphasizing how integrated purification strategy, supplier resilience, and analytics adoption collectively reduce program risk and accelerate development timelines

The analysis underscores that adenovirus purification is at an inflection point where technological choices, regional dynamics, and strategic sourcing decisions collectively determine program agility and downstream success. Purification strategy is no longer a back-office technical concern but a strategic differentiator that impacts time-to-clinic, regulatory readiness, and manufacturing cost structures. Organizations that align purification technology with application-specific requirements, qualify resilient supplier networks, and embed high-resolution analytics into process control will be better positioned to advance complex therapeutic and vaccine programs.

Looking ahead, collaboration across developers, equipment suppliers, and service providers will accelerate solutions that address both technical and commercial constraints. Adoption of platform approaches, coupled with investments in automation and validation-ready components, will continue to reduce friction during scale-up and transfer. Ultimately, stakeholders who proactively manage regulatory expectations, diversify sourcing, and prioritize process understanding will capture operational benefits and reduce program risk in a landscape that demands both speed and rigor.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Adenovirus Purification Kit Market, by Technology

  • 8.1. Chromatography
    • 8.1.1. Affinity Chromatography
    • 8.1.2. Ion Exchange Chromatography
    • 8.1.3. Size Exclusion Chromatography
  • 8.2. Filtration
    • 8.2.1. Diafiltration
    • 8.2.2. Microfiltration
    • 8.2.3. Ultrafiltration
  • 8.3. Precipitation
    • 8.3.1. Ammonium Sulfate
    • 8.3.2. Peg Precipitation

9. Adenovirus Purification Kit Market, by Scale

  • 9.1. Commercial
  • 9.2. Laboratory

10. Adenovirus Purification Kit Market, by Grade

  • 10.1. Clinical Use
  • 10.2. Research Use

11. Adenovirus Purification Kit Market, by Application

  • 11.1. Gene Therapy
  • 11.2. Research
  • 11.3. Vaccine Production

12. Adenovirus Purification Kit Market, by End User

  • 12.1. Academic Institutes
  • 12.2. Biopharmaceutical Companies
  • 12.3. Contract Manufacturing Organizations
  • 12.4. Contract Research Organizations

13. Adenovirus Purification Kit Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Adenovirus Purification Kit Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Adenovirus Purification Kit Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. United States Adenovirus Purification Kit Market

17. China Adenovirus Purification Kit Market

18. Competitive Landscape

  • 18.1. Market Concentration Analysis, 2025
    • 18.1.1. Concentration Ratio (CR)
    • 18.1.2. Herfindahl Hirschman Index (HHI)
  • 18.2. Recent Developments & Impact Analysis, 2025
  • 18.3. Product Portfolio Analysis, 2025
  • 18.4. Benchmarking Analysis, 2025
  • 18.5. Abcam PLC
  • 18.6. Bio-Rad Laboratories, Inc.
  • 18.7. Danaher Corporation
  • 18.8. Lonza Group AG
  • 18.9. Merck KGaA
  • 18.10. Promega Corporation
  • 18.11. Repligen Corporation
  • 18.12. Sartorius AG
  • 18.13. Takara Bio Inc.
  • 18.14. Thermo Fisher Scientific Inc.
  • 18.15. WuXi Biologics

LIST OF FIGURES

  • FIGURE 1. GLOBAL ADENOVIRUS PURIFICATION KIT MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL ADENOVIRUS PURIFICATION KIT MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL ADENOVIRUS PURIFICATION KIT MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL ADENOVIRUS PURIFICATION KIT MARKET SIZE, BY TECHNOLOGY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL ADENOVIRUS PURIFICATION KIT MARKET SIZE, BY SCALE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL ADENOVIRUS PURIFICATION KIT MARKET SIZE, BY GRADE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL ADENOVIRUS PURIFICATION KIT MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL ADENOVIRUS PURIFICATION KIT MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL ADENOVIRUS PURIFICATION KIT MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL ADENOVIRUS PURIFICATION KIT MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL ADENOVIRUS PURIFICATION KIT MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. UNITED STATES ADENOVIRUS PURIFICATION KIT MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 13. CHINA ADENOVIRUS PURIFICATION KIT MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL ADENOVIRUS PURIFICATION KIT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL ADENOVIRUS PURIFICATION KIT MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL ADENOVIRUS PURIFICATION KIT MARKET SIZE, BY CHROMATOGRAPHY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL ADENOVIRUS PURIFICATION KIT MARKET SIZE, BY CHROMATOGRAPHY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL ADENOVIRUS PURIFICATION KIT MARKET SIZE, BY CHROMATOGRAPHY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL ADENOVIRUS PURIFICATION KIT MARKET SIZE, BY CHROMATOGRAPHY, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL ADENOVIRUS PURIFICATION KIT MARKET SIZE, BY AFFINITY CHROMATOGRAPHY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL ADENOVIRUS PURIFICATION KIT MARKET SIZE, BY AFFINITY CHROMATOGRAPHY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL ADENOVIRUS PURIFICATION KIT MARKET SIZE, BY AFFINITY CHROMATOGRAPHY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL ADENOVIRUS PURIFICATION KIT MARKET SIZE, BY ION EXCHANGE CHROMATOGRAPHY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL ADENOVIRUS PURIFICATION KIT MARKET SIZE, BY ION EXCHANGE CHROMATOGRAPHY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL ADENOVIRUS PURIFICATION KIT MARKET SIZE, BY ION EXCHANGE CHROMATOGRAPHY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL ADENOVIRUS PURIFICATION KIT MARKET SIZE, BY SIZE EXCLUSION CHROMATOGRAPHY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL ADENOVIRUS PURIFICATION KIT MARKET SIZE, BY SIZE EXCLUSION CHROMATOGRAPHY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL ADENOVIRUS PURIFICATION KIT MARKET SIZE, BY SIZE EXCLUSION CHROMATOGRAPHY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL ADENOVIRUS PURIFICATION KIT MARKET SIZE, BY FILTRATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL ADENOVIRUS PURIFICATION KIT MARKET SIZE, BY FILTRATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL ADENOVIRUS PURIFICATION KIT MARKET SIZE, BY FILTRATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL ADENOVIRUS PURIFICATION KIT MARKET SIZE, BY FILTRATION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL ADENOVIRUS PURIFICATION KIT MARKET SIZE, BY DIAFILTRATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL ADENOVIRUS PURIFICATION KIT MARKET SIZE, BY DIAFILTRATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL ADENOVIRUS PURIFICATION KIT MARKET SIZE, BY DIAFILTRATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL ADENOVIRUS PURIFICATION KIT MARKET SIZE, BY MICROFILTRATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL ADENOVIRUS PURIFICATION KIT MARKET SIZE, BY MICROFILTRATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL ADENOVIRUS PURIFICATION KIT MARKET SIZE, BY MICROFILTRATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL ADENOVIRUS PURIFICATION KIT MARKET SIZE, BY ULTRAFILTRATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL ADENOVIRUS PURIFICATION KIT MARKET SIZE, BY ULTRAFILTRATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL ADENOVIRUS PURIFICATION KIT MARKET SIZE, BY ULTRAFILTRATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL ADENOVIRUS PURIFICATION KIT MARKET SIZE, BY PRECIPITATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL ADENOVIRUS PURIFICATION KIT MARKET SIZE, BY PRECIPITATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL ADENOVIRUS PURIFICATION KIT MARKET SIZE, BY PRECIPITATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL ADENOVIRUS PURIFICATION KIT MARKET SIZE, BY PRECIPITATION, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL ADENOVIRUS PURIFICATION KIT MARKET SIZE, BY AMMONIUM SULFATE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL ADENOVIRUS PURIFICATION KIT MARKET SIZE, BY AMMONIUM SULFATE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL ADENOVIRUS PURIFICATION KIT MARKET SIZE, BY AMMONIUM SULFATE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL ADENOVIRUS PURIFICATION KIT MARKET SIZE, BY PEG PRECIPITATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL ADENOVIRUS PURIFICATION KIT MARKET SIZE, BY PEG PRECIPITATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL ADENOVIRUS PURIFICATION KIT MARKET SIZE, BY PEG PRECIPITATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL ADENOVIRUS PURIFICATION KIT MARKET SIZE, BY SCALE, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL ADENOVIRUS PURIFICATION KIT MARKET SIZE, BY COMMERCIAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL ADENOVIRUS PURIFICATION KIT MARKET SIZE, BY COMMERCIAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL ADENOVIRUS PURIFICATION KIT MARKET SIZE, BY COMMERCIAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL ADENOVIRUS PURIFICATION KIT MARKET SIZE, BY LABORATORY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL ADENOVIRUS PURIFICATION KIT MARKET SIZE, BY LABORATORY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL ADENOVIRUS PURIFICATION KIT MARKET SIZE, BY LABORATORY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL ADENOVIRUS PURIFICATION KIT MARKET SIZE, BY GRADE, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL ADENOVIRUS PURIFICATION KIT MARKET SIZE, BY CLINICAL USE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL ADENOVIRUS PURIFICATION KIT MARKET SIZE, BY CLINICAL USE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL ADENOVIRUS PURIFICATION KIT MARKET SIZE, BY CLINICAL USE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL ADENOVIRUS PURIFICATION KIT MARKET SIZE, BY RESEARCH USE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL ADENOVIRUS PURIFICATION KIT MARKET SIZE, BY RESEARCH USE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL ADENOVIRUS PURIFICATION KIT MARKET SIZE, BY RESEARCH USE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL ADENOVIRUS PURIFICATION KIT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL ADENOVIRUS PURIFICATION KIT MARKET SIZE, BY GENE THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL ADENOVIRUS PURIFICATION KIT MARKET SIZE, BY GENE THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL ADENOVIRUS PURIFICATION KIT MARKET SIZE, BY GENE THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL ADENOVIRUS PURIFICATION KIT MARKET SIZE, BY RESEARCH, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL ADENOVIRUS PURIFICATION KIT MARKET SIZE, BY RESEARCH, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL ADENOVIRUS PURIFICATION KIT MARKET SIZE, BY RESEARCH, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL ADENOVIRUS PURIFICATION KIT MARKET SIZE, BY VACCINE PRODUCTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL ADENOVIRUS PURIFICATION KIT MARKET SIZE, BY VACCINE PRODUCTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL ADENOVIRUS PURIFICATION KIT MARKET SIZE, BY VACCINE PRODUCTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL ADENOVIRUS PURIFICATION KIT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL ADENOVIRUS PURIFICATION KIT MARKET SIZE, BY ACADEMIC INSTITUTES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL ADENOVIRUS PURIFICATION KIT MARKET SIZE, BY ACADEMIC INSTITUTES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL ADENOVIRUS PURIFICATION KIT MARKET SIZE, BY ACADEMIC INSTITUTES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL ADENOVIRUS PURIFICATION KIT MARKET SIZE, BY BIOPHARMACEUTICAL COMPANIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL ADENOVIRUS PURIFICATION KIT MARKET SIZE, BY BIOPHARMACEUTICAL COMPANIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL ADENOVIRUS PURIFICATION KIT MARKET SIZE, BY BIOPHARMACEUTICAL COMPANIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL ADENOVIRUS PURIFICATION KIT MARKET SIZE, BY CONTRACT MANUFACTURING ORGANIZATIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL ADENOVIRUS PURIFICATION KIT MARKET SIZE, BY CONTRACT MANUFACTURING ORGANIZATIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL ADENOVIRUS PURIFICATION KIT MARKET SIZE, BY CONTRACT MANUFACTURING ORGANIZATIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL ADENOVIRUS PURIFICATION KIT MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL ADENOVIRUS PURIFICATION KIT MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL ADENOVIRUS PURIFICATION KIT MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL ADENOVIRUS PURIFICATION KIT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 77. AMERICAS ADENOVIRUS PURIFICATION KIT MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 78. AMERICAS ADENOVIRUS PURIFICATION KIT MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 79. AMERICAS ADENOVIRUS PURIFICATION KIT MARKET SIZE, BY CHROMATOGRAPHY, 2018-2032 (USD MILLION)
  • TABLE 80. AMERICAS ADENOVIRUS PURIFICATION KIT MARKET SIZE, BY FILTRATION, 2018-2032 (USD MILLION)
  • TABLE 81. AMERICAS ADENOVIRUS PURIFICATION KIT MARKET SIZE, BY PRECIPITATION, 2018-2032 (USD MILLION)
  • TABLE 82. AMERICAS ADENOVIRUS PURIFICATION KIT MARKET SIZE, BY SCALE, 2018-2032 (USD MILLION)
  • TABLE 83. AMERICAS ADENOVIRUS PURIFICATION KIT MARKET SIZE, BY GRADE, 2018-2032 (USD MILLION)
  • TABLE 84. AMERICAS ADENOVIRUS PURIFICATION KIT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 85. AMERICAS ADENOVIRUS PURIFICATION KIT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 86. NORTH AMERICA ADENOVIRUS PURIFICATION KIT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 87. NORTH AMERICA ADENOVIRUS PURIFICATION KIT MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 88. NORTH AMERICA ADENOVIRUS PURIFICATION KIT MARKET SIZE, BY CHROMATOGRAPHY, 2018-2032 (USD MILLION)
  • TABLE 89. NORTH AMERICA ADENOVIRUS PURIFICATION KIT MARKET SIZE, BY FILTRATION, 2018-2032 (USD MILLION)
  • TABLE 90. NORTH AMERICA ADENOVIRUS PURIFICATION KIT MARKET SIZE, BY PRECIPITATION, 2018-2032 (USD MILLION)
  • TABLE 91. NORTH AMERICA ADENOVIRUS PURIFICATION KIT MARKET SIZE, BY SCALE, 2018-2032 (USD MILLION)
  • TABLE 92. NORTH AMERICA ADENOVIRUS PURIFICATION KIT MARKET SIZE, BY GRADE, 2018-2032 (USD MILLION)
  • TABLE 93. NORTH AMERICA ADENOVIRUS PURIFICATION KIT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 94. NORTH AMERICA ADENOVIRUS PURIFICATION KIT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 95. LATIN AMERICA ADENOVIRUS PURIFICATION KIT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 96. LATIN AMERICA ADENOVIRUS PURIFICATION KIT MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 97. LATIN AMERICA ADENOVIRUS PURIFICATION KIT MARKET SIZE, BY CHROMATOGRAPHY, 2018-2032 (USD MILLION)
  • TABLE 98. LATIN AMERICA ADENOVIRUS PURIFICATION KIT MARKET SIZE, BY FILTRATION, 2018-2032 (USD MILLION)
  • TABLE 99. LATIN AMERICA ADENOVIRUS PURIFICATION KIT MARKET SIZE, BY PRECIPITATION, 2018-2032 (USD MILLION)
  • TABLE 100. LATIN AMERICA ADENOVIRUS PURIFICATION KIT MARKET SIZE, BY SCALE, 2018-2032 (USD MILLION)
  • TABLE 101. LATIN AMERICA ADENOVIRUS PURIFICATION KIT MARKET SIZE, BY GRADE, 2018-2032 (USD MILLION)
  • TABLE 102. LATIN AMERICA ADENOVIRUS PURIFICATION KIT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 103. LATIN AMERICA ADENOVIRUS PURIFICATION KIT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 104. EUROPE, MIDDLE EAST & AFRICA ADENOVIRUS PURIFICATION KIT MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 105. EUROPE, MIDDLE EAST & AFRICA ADENOVIRUS PURIFICATION KIT MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 106. EUROPE, MIDDLE EAST & AFRICA ADENOVIRUS PURIFICATION KIT MARKET SIZE, BY CHROMATOGRAPHY, 2018-2032 (USD MILLION)
  • TABLE 107. EUROPE, MIDDLE EAST & AFRICA ADENOVIRUS PURIFICATION KIT MARKET SIZE, BY FILTRATION, 2018-2032 (USD MILLION)
  • TABLE 108. EUROPE, MIDDLE EAST & AFRICA ADENOVIRUS PURIFICATION KIT MARKET SIZE, BY PRECIPITATION, 2018-2032 (USD MILLION)
  • TABLE 109. EUROPE, MIDDLE EAST & AFRICA ADENOVIRUS PURIFICATION KIT MARKET SIZE, BY SCALE, 2018-2032 (USD MILLION)
  • TABLE 110. EUROPE, MIDDLE EAST & AFRICA ADENOVIRUS PURIFICATION KIT MARKET SIZE, BY GRADE, 2018-2032 (USD MILLION)
  • TABLE 111. EUROPE, MIDDLE EAST & AFRICA ADENOVIRUS PURIFICATION KIT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 112. EUROPE, MIDDLE EAST & AFRICA ADENOVIRUS PURIFICATION KIT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 113. EUROPE ADENOVIRUS PURIFICATION KIT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 114. EUROPE ADENOVIRUS PURIFICATION KIT MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 115. EUROPE ADENOVIRUS PURIFICATION KIT MARKET SIZE, BY CHROMATOGRAPHY, 2018-2032 (USD MILLION)
  • TABLE 116. EUROPE ADENOVIRUS PURIFICATION KIT MARKET SIZE, BY FILTRATION, 2018-2032 (USD MILLION)
  • TABLE 117. EUROPE ADENOVIRUS PURIFICATION KIT MARKET SIZE, BY PRECIPITATION, 2018-2032 (USD MILLION)
  • TABLE 118. EUROPE ADENOVIRUS PURIFICATION KIT MARKET SIZE, BY SCALE, 2018-2032 (USD MILLION)
  • TABLE 119. EUROPE ADENOVIRUS PURIFICATION KIT MARKET SIZE, BY GRADE, 2018-2032 (USD MILLION)
  • TABLE 120. EUROPE ADENOVIRUS PURIFICATION KIT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 121. EUROPE ADENOVIRUS PURIFICATION KIT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 122. MIDDLE EAST ADENOVIRUS PURIFICATION KIT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 123. MIDDLE EAST ADENOVIRUS PURIFICATION KIT MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 124. MIDDLE EAST ADENOVIRUS PURIFICATION KIT MARKET SIZE, BY CHROMATOGRAPHY, 2018-2032 (USD MILLION)
  • TABLE 125. MIDDLE EAST ADENOVIRUS PURIFICATION KIT MARKET SIZE, BY FILTRATION, 2018-2032 (USD MILLION)
  • TABLE 126. MIDDLE EAST ADENOVIRUS PURIFICATION KIT MARKET SIZE, BY PRECIPITATION, 2018-2032 (USD MILLION)
  • TABLE 127. MIDDLE EAST ADENOVIRUS PURIFICATION KIT MARKET SIZE, BY SCALE, 2018-2032 (USD MILLION)
  • TABLE 128. MIDDLE EAST ADENOVIRUS PURIFICATION KIT MARKET SIZE, BY GRADE, 2018-2032 (USD MILLION)
  • TABLE 129. MIDDLE EAST ADENOVIRUS PURIFICATION KIT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 130. MIDDLE EAST ADENOVIRUS PURIFICATION KIT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 131. AFRICA ADENOVIRUS PURIFICATION KIT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 132. AFRICA ADENOVIRUS PURIFICATION KIT MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 133. AFRICA ADENOVIRUS PURIFICATION KIT MARKET SIZE, BY CHROMATOGRAPHY, 2018-2032 (USD MILLION)
  • TABLE 134. AFRICA ADENOVIRUS PURIFICATION KIT MARKET SIZE, BY FILTRATION, 2018-2032 (USD MILLION)
  • TABLE 135. AFRICA ADENOVIRUS PURIFICATION KIT MARKET SIZE, BY PRECIPITATION, 2018-2032 (USD MILLION)
  • TABLE 136. AFRICA ADENOVIRUS PURIFICATION KIT MARKET SIZE, BY SCALE, 2018-2032 (USD MILLION)
  • TABLE 137. AFRICA ADENOVIRUS PURIFICATION KIT MARKET SIZE, BY GRADE, 2018-2032 (USD MILLION)
  • TABLE 138. AFRICA ADENOVIRUS PURIFICATION KIT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 139. AFRICA ADENOVIRUS PURIFICATION KIT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 140. ASIA-PACIFIC ADENOVIRUS PURIFICATION KIT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 141. ASIA-PACIFIC ADENOVIRUS PURIFICATION KIT MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 142. ASIA-PACIFIC ADENOVIRUS PURIFICATION KIT MARKET SIZE, BY CHROMATOGRAPHY, 2018-2032 (USD MILLION)
  • TABLE 143. ASIA-PACIFIC ADENOVIRUS PURIFICATION KIT MARKET SIZE, BY FILTRATION, 2018-2032 (USD MILLION)
  • TABLE 144. ASIA-PACIFIC ADENOVIRUS PURIFICATION KIT MARKET SIZE, BY PRECIPITATION, 2018-2032 (USD MILLION)
  • TABLE 145. ASIA-PACIFIC ADENOVIRUS PURIFICATION KIT MARKET SIZE, BY SCALE, 2018-2032 (USD MILLION)
  • TABLE 146. ASIA-PACIFIC ADENOVIRUS PURIFICATION KIT MARKET SIZE, BY GRADE, 2018-2032 (USD MILLION)
  • TABLE 147. ASIA-PACIFIC ADENOVIRUS PURIFICATION KIT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 148. ASIA-PACIFIC ADENOVIRUS PURIFICATION KIT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 149. GLOBAL ADENOVIRUS PURIFICATION KIT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 150. ASEAN ADENOVIRUS PURIFICATION KIT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 151. ASEAN ADENOVIRUS PURIFICATION KIT MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 152. ASEAN ADENOVIRUS PURIFICATION KIT MARKET SIZE, BY CHROMATOGRAPHY, 2018-2032 (USD MILLION)
  • TABLE 153. ASEAN ADENOVIRUS PURIFICATION KIT MARKET SIZE, BY FILTRATION, 2018-2032 (USD MILLION)
  • TABLE 154. ASEAN ADENOVIRUS PURIFICATION KIT MARKET SIZE, BY PRECIPITATION, 2018-2032 (USD MILLION)
  • TABLE 155. ASEAN ADENOVIRUS PURIFICATION KIT MARKET SIZE, BY SCALE, 2018-2032 (USD MILLION)
  • TABLE 156. ASEAN ADENOVIRUS PURIFICATION KIT MARKET SIZE, BY GRADE, 2018-2032 (USD MILLION)
  • TABLE 157. ASEAN ADENOVIRUS PURIFICATION KIT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 158. ASEAN ADENOVIRUS PURIFICATION KIT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 159. GCC ADENOVIRUS PURIFICATION KIT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 160. GCC ADENOVIRUS PURIFICATION KIT MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 161. GCC ADENOVIRUS PURIFICATION KIT MARKET SIZE, BY CHROMATOGRAPHY, 2018-2032 (USD MILLION)
  • TABLE 162. GCC ADENOVIRUS PURIFICATION KIT MARKET SIZE, BY FILTRATION, 2018-2032 (USD MILLION)
  • TABLE 163. GCC ADENOVIRUS PURIFICATION KIT MARKET SIZE, BY PRECIPITATION, 2018-2032 (USD MILLION)
  • TABLE 164. GCC ADENOVIRUS PURIFICATION KIT MARKET SIZE, BY SCALE, 2018-2032 (USD MILLION)
  • TABLE 165. GCC ADENOVIRUS PURIFICATION KIT MARKET SIZE, BY GRADE, 2018-2032 (USD MILLION)
  • TABLE 166. GCC ADENOVIRUS PURIFICATION KIT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 167. GCC ADENOVIRUS PURIFICATION KIT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 168. EUROPEAN UNION ADENOVIRUS PURIFICATION KIT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 169. EUROPEAN UNION ADENOVIRUS PURIFICATION KIT MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 170. EUROPEAN UNION ADENOVIRUS PURIFICATION KIT MARKET SIZE, BY CHROMATOGRAPHY, 2018-2032 (USD MILLION)
  • TABLE 171. EUROPEAN UNION ADENOVIRUS PURIFICATION KIT MARKET SIZE, BY FILTRATION, 2018-2032 (USD MILLION)
  • TABLE 172. EUROPEAN UNION ADENOVIRUS PURIFICATION KIT MARKET SIZE, BY PRECIPITATION, 2018-2032 (USD MILLION)
  • TABLE 173. EUROPEAN UNION ADENOVIRUS PURIFICATION KIT MARKET SIZE, BY SCALE, 2018-2032 (USD MILLION)
  • TABLE 174. EUROPEAN UNION ADENOVIRUS PURIFICATION KIT MARKET SIZE, BY GRADE, 2018-2032 (USD MILLION)
  • TABLE 175. EUROPEAN UNION ADENOVIRUS PURIFICATION KIT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 176. EUROPEAN UNION ADENOVIRUS PURIFICATION KIT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 177. BRICS ADENOVIRUS PURIFICATION KIT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 178. BRICS ADENOVIRUS PURIFICATION KIT MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 179. BRICS ADENOVIRUS PURIFICATION KIT MARKET SIZE, BY CHROMATOGRAPHY, 2018-2032 (USD MILLION)
  • TABLE 180. BRICS ADENOVIRUS PURIFICATION KIT MARKET SIZE, BY FILTRATION, 2018-2032 (USD MILLION)
  • TABLE 181. BRICS ADENOVIRUS PURIFICATION KIT MARKET SIZE, BY PRECIPITATION, 2018-2032 (USD MILLION)
  • TABLE 182. BRICS ADENOVIRUS PURIFICATION KIT MARKET SIZE, BY SCALE, 2018-2032 (USD MILLION)
  • TABLE 183. BRICS ADENOVIRUS PURIFICATION KIT MARKET SIZE, BY GRADE, 2018-2032 (USD MILLION)
  • TABLE 184. BRICS ADENOVIRUS PURIFICATION KIT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 185. BRICS ADENOVIRUS PURIFICATION KIT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 186. G7 ADENOVIRUS PURIFICATION KIT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 187. G7 ADENOVIRUS PURIFICATION KIT MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 188. G7 ADENOVIRUS PURIFICATION KIT MARKET SIZE, BY CHROMATOGRAPHY, 2018-2032 (USD MILLION)
  • TABLE 189. G7 ADENOVIRUS PURIFICATION KIT MARKET SIZE, BY FILTRATION, 2018-2032 (USD MILLION)
  • TABLE 190. G7 ADENOVIRUS PURIFICATION KIT MARKET SIZE, BY PRECIPITATION, 2018-2032 (USD MILLION)
  • TABLE 191. G7 ADENOVIRUS PURIFICATION KIT MARKET SIZE, BY SCALE, 2018-2032 (USD MILLION)
  • TABLE 192. G7 ADENOVIRUS PURIFICATION KIT MARKET SIZE, BY GRADE, 2018-2032 (USD MILLION)
  • TABLE 193. G7 ADENOVIRUS PURIFICATION KIT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 194. G7 ADENOVIRUS PURIFICATION KIT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 195. NATO ADENOVIRUS PURIFICATION KIT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 196. NATO ADENOVIRUS PURIFICATION KIT MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 197. NATO ADENOVIRUS PURIFICATION KIT MARKET SIZE, BY CHROMATOGRAPHY, 2018-2032 (USD MILLION)
  • TABLE 198. NATO ADENOVIRUS PURIFICATION KIT MARKET SIZE, BY FILTRATION, 2018-2032 (USD MILLION)
  • TABLE 199. NATO ADENOVIRUS PURIFICATION KIT MARKET SIZE, BY PRECIPITATION, 2018-2032 (USD MILLION)
  • TABLE 200. NATO ADENOVIRUS PURIFICATION KIT MARKET SIZE, BY SCALE, 2018-2032 (USD MILLION)
  • TABLE 201. NATO ADENOVIRUS PURIFICATION KIT MARKET SIZE, BY GRADE, 2018-2032 (USD MILLION)
  • TABLE 202. NATO ADENOVIRUS PURIFICATION KIT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 203. NATO ADENOVIRUS PURIFICATION KIT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 204. GLOBAL ADENOVIRUS PURIFICATION KIT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 205. UNITED STATES ADENOVIRUS PURIFICATION KIT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 206. UNITED STATES ADENOVIRUS PURIFICATION KIT MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 207. UNITED STATES ADENOVIRUS PURIFICATION KIT MARKET SIZE, BY CHROMATOGRAPHY, 2018-2032 (USD MILLION)
  • TABLE 208. UNITED STATES ADENOVIRUS PURIFICATION KIT MARKET SIZE, BY FILTRATION, 2018-2032 (USD MILLION)
  • TABLE 209. UNITED STATES ADENOVIRUS PURIFICATION KIT MARKET SIZE, BY PRECIPITATION, 2018-2032 (USD MILLION)
  • TABLE 210. UNITED STATES ADENOVIRUS PURIFICATION KIT MARKET SIZE, BY SCALE, 2018-2032 (USD MILLION)
  • TABLE 211. UNITED STATES ADENOVIRUS PURIFICATION KIT MARKET SIZE, BY GRADE, 2018-2032 (USD MILLION)
  • TABLE 212. UNITED STATES ADENOVIRUS PURIFICATION KIT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 213. UNITED STATES ADENOVIRUS PURIFICATION KIT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 214. CHINA ADENOVIRUS PURIFICATION KIT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 215. CHINA ADENOVIRUS PURIFICATION KIT MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 216. CHINA ADENOVIRUS PURIFICATION KIT MARKET SIZE, BY CHROMATOGRAPHY, 2018-2032 (USD MILLION)
  • TABLE 217. CHINA ADENOVIRUS PURIFICATION KIT MARKET SIZE, BY FILTRATION, 2018-2032 (USD MILLION)
  • TABLE 218. CHINA ADENOVIRUS PURIFICATION KIT MARKET SIZE, BY PRECIPITATION, 2018-2032 (USD MILLION)
  • TABLE 219. CHINA ADENOVIRUS PURIFICATION KIT MARKET SIZE, BY SCALE, 2018-2032 (USD MILLION)
  • TABLE 220. CHINA ADENOVIRUS PURIFICATION KIT MARKET SIZE, BY GRADE, 2018-2032 (USD MILLION)
  • TABLE 221. CHINA ADENOVIRUS PURIFICATION KIT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 222. CHINA ADENOVIRUS PURIFICATION KIT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)